No Data
No Data
No Data
No Data
No Data
Health Source (600380.SH): TG-1000 capsule phase III clinical trial reached the main end
Gelonghui, April 17 | Health Source (600380.SH) announced that recently, the company's innovative drug product TG-1000 capsules for use in a multi-center phase III clinical trial (referred to as this study) with no complications in acute influenza A and B infections aged 12 and above (referred to as this study) reached the end of the main study. The company will communicate with the Drug Evaluation Center (CDE) of the China Drug Administration about the marketing application of TG-1000 capsules to treat influenza in the near future to advance the marketing process of TG-1000 capsules.
Gelonghui FinanceApr 17 06:32 ET
Some May Be Optimistic About Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) Earnings
The market for Joincare Pharmaceutical Group Industry Co.,Ltd.'s (SHSE:600380) shares didn't move much after it posted weak earnings recently. We did some digging, and we believe the earnings are str
Simply Wall StApr 10 19:23 ET
Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Sheds 6.5% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. To
Simply Wall StMar 25 18:45 ET
Are Strong Financial Prospects The Force That Is Driving The Momentum In Joincare Pharmaceutical Group Industry Co.,Ltd.'s SHSE:600380) Stock?
Joincare Pharmaceutical Group IndustryLtd's (SHSE:600380) stock is up by a considerable 17% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that i
Simply Wall StMar 4 17:10 ET
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug
Livzon Pharmaceutical Group (HKG:1513, SHE:000513), a unit of Joincare Pharmaceutical (SHA:600380), will conduct clinical trials on JP-1366 tablets after obtaining the approval of China's National Med
MT NewswiresFeb 23 00:56 ET
Health Source (600380.SH): JP-1366 tablets obtained approval notice for drug clinical trials
On February 22, Ge Longhui Health Yuan (600380.SH) announced that the company's holding subsidiary, Livou Group Livzon Pharmaceutical Research Institute (hereinafter: Lizhu Research Institute), a wholly-owned subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” (Notice Number: 2024LP00422) approved and issued by the State Drug Administration and approved JP-1366 tablets to conduct clinical trials. The first phase of JP-1366 was developed by Onconic Therapeutics Inc. (Onconic) in South Korea
Gelonghui FinanceFeb 22 05:06 ET
No Data
No Data